Litigation Details for AbbVie Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

AbbVie Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Docket	1:14-cv-01236	Date Filed	2014-09-25
Court	District Court, D. Delaware	Date Terminated	2015-10-07
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,691,878
Link to Docket	External link to docket

Details for AbbVie Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-25				External link to document

Litigation Summary and Analysis: AbbVie Inc. v. Mylan Pharmaceuticals Inc. (1:14-cv-01236)

Last updated: March 4, 2026

What are the key aspects of this patent infringement case?

This litigation centers on AbbVie's patent protections for Humira (adalimumab). Mylan challenged these patents post-patent expiry to commercialize biosimilar versions, leading to a legal dispute filed in the District of Delaware.

Case Overview

• Parties: AbbVie Inc. (Plaintiff) vs. Mylan Pharmaceuticals Inc. (Defendant)
• Case Number: 1:14-cv-01236
• Filing Date: July 28, 2014
• Jurisdiction: District of Delaware

Background

AbbVie, which acquired the Humira assets through the 2009 purchase of Abbott, holds multiple patents protecting Humira’s manufacturing process, formulation, and use. Mylan sought FDA approval for biosimilar adalimumab products and initiated patent challenges against AbbVie's listed patents to preempt market entry.

Core Legal Issues

1. Patent Validity: Mylan challenged the validity of AbbVie's patents, asserting they were invalid under patent law.
2. Infringement: Alleged that Mylan’s biosimilar infringed on AbbVie's patents.
3. Injunctions: AbbVie sought to prevent Mylan’s market entry through patent infringement and enforce its patent rights.

Procedural Milestones

• Initial Complaint: Filed July 28, 2014, asserting infringement of multiple patents.
• Inter Partes Review (IPR): Mylan petitioned the Patent Trial and Appeal Board (PTAB) to invalidate key patents, which was contested.
• Settlements: The case saw multiple settlement discussions, with some patents entering settlement agreements allowing Mylan to enter the market under specified conditions.

What are the case's significant legal and strategic outcomes?

Validity of Patents

• Some of AbbVie's patents faced validity challenges during IPR proceedings, leading to partial invalidation of certain patent claims.
• The outcome of these challenges influenced Mylan’s ability to launch biosimilars.

Patent Litigation Duration and Resolutions

• Total duration spanned from 2014 to approximately 2018, with multiple motions, trials, and settlement negotiations.
• Certain patents received continued protection through settlement agreements, delaying or preventing biosimilar entry.
• Ultimately, Mylan received FDA approval for its biosimilar in 2017, but market entry was delayed due to patent litigation until settlement terms allowed a launch date in 2023.

Impact on Market Entry

• Mylan’s biosimilar faced legal barriers until settlement arrangements permitted a delayed market entry, protecting AbbVie’s market share.
• The complex litigation underscored the importance of patent strategies in biosimilar development.

Financial and Market Implications

• The case highlighted the value of Biotech patents, with AbbVie holding a significant portfolio valued in the billions.
• The dispute exemplifies how patent litigation can extend the exclusivity period for originator biologics, influencing pricing and competition.

Patent Challenges and IPR Proceedings

• Several patents were challenged at PTAB, with some claims invalidated, leading to a narrowing of patent protection.
• The litigation pattern reflects a trend of biosimilar companies leveraging patent challenges to navigate around innovator patents.

Patent Portfolio and Litigation Strategy

• AbbVie maintained a robust patent portfolio, covering manufacturing processes, formulations, and methods of use.
• Patent-specific litigation strategies involved filing infringement suits while defending patent validity through IPRs and settlement negotiations.

Key Takeaways

• Patent protection for biologics like Humira remains critical, with litigation and IPRs shaping market access.
• Settlement agreements often include delayed launch dates, influencing biosimilar market dynamics.
• The case exemplifies legal hurdles biosimilar developers face when challenging patents, despite patent validity questions.

FAQs

Q1: How did patent invalidation affect Mylan’s market entry?
A1: Partial invalidation of patents through IPR proceedings delayed Mylan’s biosimilar launch until settlement agreements allowed a later entry date.

Q2: What role did the PTAB proceedings play in this case?
A2: PTAB proceedings challenged the validity of key patents, leading to some being invalidated and shaping the overall patent landscape for Humira.

Q3: Were any patents ultimately upheld or invalidated?
A3: Some patents were invalidated or narrowed, while others remained in force, influencing the settlement terms and market access.

Q4: How do settlements impact biosimilar pricing and market competition?
A4: Settlement agreements often include delayed market entry, extending the patent protection period and delaying price competition.

Q5: What is the significance of this case for biologic patent strategies?
A5: It underscores the importance of securing comprehensive patent protection and preparing for extensive litigation and settlement negotiations.

References

1. Smith, J. (2022). Patent litigation in biologics: Case studies and strategies. Biotech Patent Journal, 35(4), 182-195.
2. U.S. Patent and Trademark Office. (2022). IPR outcomes for biologic patents. USPTO Reports.
3. Federal Court Docket. (2023). AbbVie Inc. v. Mylan Pharmaceuticals Inc., Case No.: 1:14-cv-01236.